Literature DB >> 1677885

H2 antagonist and omeprazole nonresponders.

V Savarino, G S Mela, S Vigneri, G Celle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1677885     DOI： 10.1007/bf01297469

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  11 in total

1.  Omeprazole in H2 blocker non-responders.

Authors:  V Savarino; G Mela; A Sumberaz; G Celle
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

2.  Binding assay to predict response to H2-antagonists.

Authors:  K A Heald; J W Fielding; F Macdonald
Journal:  Lancet       Date:  1989-02-11       Impact factor: 79.321

3.  Gastric aspiration versus antimony and glass pH electrodes. A simultaneous comparative in vivo study.

Authors:  V Savarino; G S Mela; P Zentilin; M R Magnolia; P Scalabrini; F Valle; M Moretti; G Bonifacino; G Celle
Journal:  Scand J Gastroenterol       Date:  1989-05       Impact factor: 2.423

4.  Duodenal ulcer resistant to usual omeprazole dose.

Authors:  V Savarino; G S Mela; P Zentilin; G Celle
Journal:  Am J Gastroenterol       Date:  1990-05       Impact factor: 10.864

5.  Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).

Authors:  M J Collen; V J Stanczak; C A Ciarleglio
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

6.  H2-receptor antagonist non-responders.

Authors:  V Savarino; G S Mela; P Scalabrini; G Celle
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

7.  Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.

Authors:  S Lanzon-Miller; R E Pounder; M R Hamilton; S Ball; N A Chronos; F Raymond; M Olausson; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

8.  Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.

Authors:  E C Klinkenberg-Knol; S G Meuwissen
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

Review 9.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

10.  Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.

Authors:  P N Maton; R Vinayek; H Frucht; K A McArthur; L S Miller; Z A Saeed; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1989-10       Impact factor: 22.682
View more
  2 in total

Review 1.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

2.  Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.

Authors:  V Savarino; G S Mela; P Zentilin; P Cutela; M R Mele; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.